🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are escalating globally, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the reality of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Authorization

Zoliflodacin, also known as a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This approval marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

According to findings released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines a dual-drug approach. The study enrolled hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced positive views. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for managing the epidemic. This is deemed crucial to reduce the burden of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.